clinical trial

The test, called LifeKit Prevent, analyzes microbial genomic biomarkers in stool samples that are strongly associated with specific stages of CRC progression.

Moderna's vaccine triggers antibody response specifically to the anti-receptor binding domain antibodies of the SARS-CoV-2 spike protein.

The randomized, Phase II trial will test ctDNA-guided second-line adjuvant therapy for stage II and III hormone receptor-positive, HER-2 negative breast cancer.

The nationwide study will enroll prostate cancer patients who do and don't meet current guidelines and assess how access to genetic information impacts their care. 

The kit, which received EUA from the FDA in May, will be used to test clinical samples from patients at D-HH member hospitals.

Caris will sequence DNA and RNA for certain cancer patients and potentially help Merus enroll cancer patients with NRG1 fusions in the Phase I/II eNRGy trial for zenocutuzumab.